You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo Nordisk
since
auto-detected in 140 stories
2 days ago
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
3 days ago
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss ⊖
found
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Stocks making the biggest moves midday: IBM, AMD, Dillard's, Novo Nordisk, Keysight Technologies & more ○
These are the stocks posting the largest moves in midday trading.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
4 days ago
Eli Lilly's lead in the obesity race gets wider after another win against rival Novo Nordisk ⊕
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
Jim Cramer's top 10 things to watch in the stock market Monday ⊕
President Trump is raising his threatened global tariff to 15%, and Eli Lilly triumphs over obesity rival Novo Nordisk once again.
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more ○
These are the stocks posting the largest moves in premarket trading.
12 days ago
Weight-loss race: how switch from injections to pills is expanding big pharma’s hopes ⊕⊕
found
a story from The Guardian ⚠️ › International
Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade
“I just felt slow: I want to be able to do anything my kids want to do and not have weight b…
17 days ago
The race for cheaper GLP-1 drugs is hitting legal limits ⊖
found
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and ris…
18 days ago
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims ⊖⊖
The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.